Why precision medicine needed a new integrated commercial solution

The potential of precision medicine to revolutionize patient care is undeniable, yet its widespread impact is limited by significant challenges within the current healthcare and diagnostic landscape. Access to breakthrough therapies remains constrained due to inefficient diagnostic pathways, as highlighted by research showing that over 60.4%[i] of patients do not have access to these therapies. Moreover, many legacy commercial support providers are ill-equipped to meet the complex needs of precision medicine, with nearly 40%[ii] of therapies launched before 2020 failing to deliver a sustainable return on investment. Diaceutics recognized these barriers and developed PMx, an integrated commercialization platform that aligns diagnostic and therapeutic processes to ensure more patients can access the life-changing potential of precision medicine.

Introducing PMx

Diaceutics’ PMx is a cutting-edge suite of data-driven services built for the promotion and commercialization of precision medicines. Officially launched in August 2024, PMx leverages Diaceutics’ best-in-class genomic lab data, extensive Lab Network, omni-channel marketing and peer-to-peer physician education to streamline the process of bringing precision medicines to market. By integrating diagnostics and treatment pathways, PMx ensures that patients are accurately identified based on their genomic profiles and offered the optimal therapy for their condition.

PMx not only addresses inefficiencies in diagnostic pathways but also offers a comprehensive solution that reduces costs and enhances ROI for pharmaceutical companies. By providing a full suite of services—ranging from patient identification and recruitment to diagnostic test adoption and physician engagement—PMx bridges the gap between precision medicine’s promise and its real-world impact.

The vision behind PMx: Expanding access to precision medicine

PMx was developed with a clear mission: to make precision medicine accessible to a broader audience and create a sustainable model for future innovation. Our decision to launch PMx was driven by three key factors:

1. Focus on patient access: With over 1,500 customer engagements spanning nearly two decades, Diaceutics have witnessed firsthand how breakthrough therapies can transform patient outcomes. However, we've also seen inefficiencies in diagnostic pathways which continue to limit 60.4% of patients[i] from accessing these therapies. Precision medicine holds the potential to benefit all patients, but today, it reaches only a few.

2. Limitations of legacy providers: The pharma sector, with an annual market valued at over $200 billion2, has long relied on legacy commercial support providers. Yet, these legacy providers have struggled to adequately adapt to the unique requirements of precision medicine. Many of these providers have struggled to adapt to the complex needs of precision medicine, resulting in up to 40% of therapies launched before 2020 failing to achieve a viable ROI[ii]. Pharma companies are now seeking more integrated, adaptable partners to navigate the challenges of combining diagnostic and therapeutic solutions.

3. A data-led approach: Recognizing an opportunity to revolutionize traditional commercial models, Diaceutics developed PMx to replace outdated approaches with a data-driven, integrated solution. By merging diagnostic and treatment pathways, PMx enables seamless clinical decision-making, ensuring patients receive the right treatment at the right time.

A journey of continuous innovation

Our journey with PMx has been one of continuous innovation. We began by building a robust data supply that identified diagnostic barriers to treatment and these insights are now widely published. Additionally, we expanded our Lab Network, which now includes over 1,200 labs, to support real-time decision-making in prescribing. Through these labs, thousands of physicians are informed about new test and drug combinations at critical moments of care, ensuring that the right information reaches those who need it most.

The DXRX platform: Scaling precision medicine commercialization

To make these capabilities scalable, we developed the DXRX platform, the only digital commercialization platform dedicated to precision medicine. DXRX provides cost-efficient, just-in-time physician engagement tools that help convert test results into actionable treatment decisions. This platform also offers our pharma customers with unparalleled visibility into their commercialization efforts.

Looking ahead

Our short-term goal for PMx is to increase patient treatment access by 50% while reducing costs by half. We believe this will unlock new opportunities for reinvestment in precision medicine infrastructure and next-generation therapies.

We are thankful to our investors who shared our vision for disrupting precision medicine commercialization and to our lab partners who co-developed this innovative model. At Diaceutics, every team member understands the significant opportunity PMx presents to bring precision medicine to a broader audience and support its future potential.

Looking forward, PMx represents more than just a solution to today’s challenges—it’s a catalyst for the future of healthcare. By continuing to innovate, scale, and refine our platform, we aim to empower stakeholders across the healthcare ecosystem to deliver the right treatment to the right patient at the right time. As we expand our global reach and deepen our capabilities, our focus remains clear: to make precision medicine the standard of care for all, ensuring that every patient has access to the transformative therapies they need. This is the promise of PMx, and we are committed to seeing it realized.

References:

[i] Sadik, H., Pritchard, D., Keeling, D.-M., Policht, F., Riccelli, P., Stone, G., Finkel, K., Schreier, J., & Munksted, S. (2022). Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non–Small-Cell Lung Cancer. JCO Precision Oncology, 6, e2200246

[ii] Henderson, R. H., French, D., Stewart, E., Smart, D., Idica, A., Redmond, S., Eckstein, M., Clark, J., Sullivan, R., Keeling, P., & Lawler, M. (2023). Delivering the precision oncology paradigm: reduced R&D costs and greater return on investment through a companion diagnostic informed precision oncology medicines approach. Journal of Pharmaceutical Policy and Practice, 16(84).

[iii] RNS Announcement: Diaceutics. (2024). Diaceutics Launches PMx: A Revolutionary Platform for Precision Medicine. Retrieved from RNS Announcement